|
US9249423B2
(en)
|
2007-02-02 |
2016-02-02 |
Yale University |
Method of de-differentiating and re-differentiating somatic cells using RNA
|
|
US10155038B2
(en)
|
2007-02-02 |
2018-12-18 |
Yale University |
Cells prepared by transient transfection and methods of use thereof
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
IL288241B2
(en)
*
|
2012-06-11 |
2023-10-01 |
Wilson Wolf Mfg Corporation |
Improved cell culture methods for stress cell therapy
|
|
IN2015KN00329A
(enExample)
|
2012-08-09 |
2015-07-10 |
Univ Leland Stanford Junior |
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
AU2014214850C1
(en)
*
|
2013-02-06 |
2018-12-06 |
Celgene Corporation |
Modified T lymphocytes having improved specificity
|
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
|
LT2958943T
(lt)
|
2013-02-20 |
2020-01-27 |
The Trustees Of The University Of Pennsylvania |
Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
CA2907397C
(en)
|
2013-03-15 |
2022-11-22 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
EP2986636B1
(en)
|
2013-04-17 |
2018-11-14 |
Baylor College Of Medicine |
Immunosuppressive tgf-beta signal converter
|
|
CN105431456A
(zh)
*
|
2013-06-14 |
2016-03-23 |
休斯敦系统大学 |
用修饰的嵌合抗原受体靶向肿瘤新生血管
|
|
JP6585041B2
(ja)
*
|
2013-07-18 |
2019-10-02 |
ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ |
免疫細胞の能力を増強する方法
|
|
CN105764926A
(zh)
|
2013-09-24 |
2016-07-13 |
梅迪塞纳医疗股份有限公司 |
白介素-4受体结合融合蛋白及其应用
|
|
CA2931684C
(en)
|
2013-12-19 |
2024-02-20 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
WO2015112626A1
(en)
|
2014-01-21 |
2015-07-30 |
June Carl H |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
IL322264A
(en)
|
2014-04-07 |
2025-09-01 |
Novartis Ag |
Cancer treatment using chimeric antigen receptor (CAR) against CD19
|
|
US20170158749A1
(en)
*
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP6736540B2
(ja)
|
2014-07-21 |
2020-08-05 |
ノバルティス アーゲー |
Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
|
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
|
MY181834A
(en)
|
2014-07-21 |
2021-01-08 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
JP6631865B2
(ja)
*
|
2014-08-11 |
2020-01-15 |
日本化薬株式会社 |
ＴＧＦβ阻害機能を持つキメラタンパク質
|
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
ES2891332T3
(es)
|
2014-09-17 |
2022-01-27 |
Novartis Ag |
Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
|
|
AU2015330898B2
(en)
|
2014-10-08 |
2022-03-10 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
MA41538A
(fr)
*
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
|
CN107567461A
(zh)
|
2014-12-29 |
2018-01-09 |
诺华股份有限公司 |
制备嵌合抗原受体表达细胞的方法
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
EP4223873A3
(en)
|
2015-01-31 |
2023-09-06 |
The Trustees of the University of Pennsylvania |
Compositions and methods for t cell delivery of therapeutic molecules
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
CN107530376A
(zh)
|
2015-02-18 |
2018-01-02 |
恩立夫克治疗有限责任公司 |
用于癌症治疗的联合免疫疗法和细胞因子控制疗法
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
CN107531805A
(zh)
|
2015-03-05 |
2018-01-02 |
弗雷德哈钦森癌症研究中心 |
免疫调节融合蛋白及其用途
|
|
WO2016154112A1
(en)
*
|
2015-03-20 |
2016-09-29 |
Children's National Medical Center |
Generating virus or other antigen-specific t cells from a naive t cell population
|
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
AU2016249005B2
(en)
|
2015-04-17 |
2022-06-16 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
IL287500B2
(en)
|
2015-04-21 |
2023-12-01 |
Enlivex Therapeutics Rdo Ltd |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CN104910279B
(zh)
*
|
2015-06-05 |
2019-02-22 |
重庆精准生物技术有限公司 |
靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用
|
|
WO2017015427A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
GB201514875D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Receptor
|
|
CN116334205A
(zh)
|
2015-09-03 |
2023-06-27 |
诺华股份有限公司 |
预测细胞因子释放综合征的生物标志物
|
|
GB201518816D0
(en)
*
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Receptor
|
|
CN108699557B
(zh)
|
2015-12-04 |
2025-08-15 |
诺华股份有限公司 |
用于免疫肿瘤学的组合物和方法
|
|
PT3393504T
(pt)
|
2015-12-22 |
2025-12-30 |
Novartis Ag |
Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
|
|
CA3014885A1
(en)
|
2016-02-18 |
2017-08-24 |
Enlivex Therapeutics Ltd. |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
CN108884460B
(zh)
*
|
2016-03-19 |
2023-04-28 |
埃克苏马生物技术公司 |
淋巴细胞转导及其扩增调节的方法与组合物
|
|
US11325948B2
(en)
|
2016-03-19 |
2022-05-10 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
|
|
US12590321B2
(en)
|
2016-03-19 |
2026-03-31 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
SG11201901642XA
(en)
*
|
2016-08-26 |
2019-03-28 |
Baylor College Medicine |
Constitutively active cytokine receptors for cell therapy
|
|
WO2018067992A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
WO2018075820A2
(en)
|
2016-10-20 |
2018-04-26 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
|
DK3541833T5
(da)
|
2016-11-17 |
2024-09-02 |
2Seventy Bio Inc |
TGFß signalkonverter
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
GB201702617D0
(en)
*
|
2017-02-17 |
2017-04-05 |
Autolus Ltd |
Receptor
|
|
KR102879522B1
(ko)
*
|
2017-03-03 |
2025-11-04 |
엑수마 바이오테크, 코포레이션 |
림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물
|
|
MX2019010812A
(es)
|
2017-03-17 |
2019-12-11 |
Hutchinson Fred Cancer Res |
Proteinas de fusion inmunomoduladoras y sus usos.
|
|
KR20190130608A
(ko)
|
2017-03-22 |
2019-11-22 |
노파르티스 아게 |
면역종양학을 위한 조성물 및 방법
|
|
JP2020516654A
(ja)
|
2017-04-13 |
2020-06-11 |
センティ バイオサイエンシズ インコーポレイテッド |
組み合わせがん免疫療法
|
|
CA3078434A1
(en)
|
2017-10-10 |
2019-04-18 |
Medicenna Therapeutics, Inc. |
Il-4-fusion formulations for treatment of central nervous system (cns) tumors
|
|
KR20200086278A
(ko)
|
2017-10-18 |
2020-07-16 |
노파르티스 아게 |
선택적 단백질 분해를 위한 조성물 및 방법
|
|
CN109880803B
(zh)
*
|
2017-12-06 |
2024-06-07 |
恺兴生命科技(上海)有限公司 |
嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
EP3759132A1
(en)
*
|
2018-03-02 |
2021-01-06 |
Allogene Therapeutics, Inc. |
Inducible chimeric cytokine receptors
|
|
WO2019173324A1
(en)
|
2018-03-06 |
2019-09-12 |
The Trustees Of The University Of Pennsylvania |
Prostate-specific membrane antigen cars and methods of use thereof
|
|
CA3102097A1
(en)
*
|
2018-06-01 |
2019-12-05 |
The Board Of Trustees Of The Leland Stanford Junior Unversity |
Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
|
|
US12404497B2
(en)
|
2018-06-01 |
2025-09-02 |
Medicenna Therapeutics Inc. |
Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
AU2019284911B2
(en)
|
2018-06-13 |
2026-04-09 |
Novartis Ag |
BCMA chimeric antigen receptors and uses thereof
|
|
CN110615843B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含第三信号受体的嵌合抗原受体及其应用
|
|
US11419898B2
(en)
|
2018-10-17 |
2022-08-23 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
TW202035685A
(zh)
|
2018-10-17 |
2020-10-01 |
美商聖堤生物科技股份有限公司 |
組合癌症免疫療法
|
|
US20200147137A1
(en)
*
|
2018-11-08 |
2020-05-14 |
WUGEN, Inc. |
Compositions and methods for treatment of cancer
|
|
CN116479022A
(zh)
*
|
2018-12-12 |
2023-07-25 |
中南大学 |
一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
|
|
BR112021017365A2
(pt)
|
2019-03-01 |
2022-02-01 |
Allogene Therapeutics Inc |
Receptores de citocina quiméricos constitutivamente ativos
|
|
AU2020232216B2
(en)
*
|
2019-03-01 |
2025-09-25 |
Allogene Therapeutics, Inc. |
Chimeric cytokine receptors bearing a PD-1 ectodomain
|
|
MX2021013588A
(es)
|
2019-05-08 |
2022-02-11 |
Medigene Immunotherapies Gmbh |
Células t genomodificadas.
|
|
US12485180B2
(en)
|
2019-08-30 |
2025-12-02 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
|
US12528856B2
(en)
|
2019-08-30 |
2026-01-20 |
Allogene Therapeutics, Inc. |
Chimeric cytokine receptors comprising TGF β binding domains
|
|
KR102275668B1
(ko)
*
|
2019-09-26 |
2021-07-12 |
충북대학교 산학협력단 |
면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
|
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
KR20220104217A
(ko)
|
2019-11-26 |
2022-07-26 |
노파르티스 아게 |
Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
|
|
CA3167065A1
(en)
|
2020-02-24 |
2021-09-02 |
Regina Junhui LIN |
Bcma car-t cells with enhanced activities
|
|
US20230138428A1
(en)
|
2020-02-25 |
2023-05-04 |
Quell Therapeutics Limited |
Chimeric receptors for use in engineered cells
|
|
IL301014A
(en)
|
2020-08-31 |
2023-05-01 |
Univ Yale |
Compositions and methods for delivery of nucleic acids to cells
|
|
KR20240057435A
(ko)
*
|
2021-09-17 |
2024-05-02 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
인터류킨-9 수용체 신호전달 도메인을 포함하는 키메라 항원 수용체
|
|
IL316032A
(en)
|
2022-04-08 |
2024-11-01 |
Regeneron Pharma |
Multicomponent receptor and signaling complexes
|
|
AU2023406926A1
(en)
|
2022-12-01 |
2025-06-26 |
Yale University |
Stimuli-responsive traceless engineering platform for intracellular payload delivery
|
|
CN120225568A
(zh)
*
|
2022-12-27 |
2025-06-27 |
广州瑞风生物科技有限公司 |
一种融合蛋白及其应用
|
|
EP4403580A1
(en)
|
2023-01-23 |
2024-07-24 |
Medizinische Hochschule Hannover |
Anti-entpd3 chimeric antigen receptor
|
|
TW202436337A
(zh)
|
2023-01-23 |
2024-09-16 |
漢諾威醫學院 |
嵌合抗原受體
|
|
AU2024219048A1
(en)
|
2023-02-07 |
2025-08-07 |
Quell Therapeutics Limited |
Culture method for treg cells
|
|
EP4669343A1
(en)
|
2023-02-24 |
2025-12-31 |
Medizinische Hochschule Hannover |
CHIMERIC ANTIGEN RECIPIENT
|
|
EP4420676A1
(en)
|
2023-02-24 |
2024-08-28 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
CN116284449B
(zh)
*
|
2023-02-27 |
2024-11-19 |
深圳市先康达生命科学有限公司 |
增强型TGF-βR嵌合受体及其应用
|
|
JP2026507228A
(ja)
|
2023-03-03 |
2026-02-27 |
アーセナル バイオサイエンシズ インコーポレイテッド |
Ｐｓｍａ及びｃａ９を標的とするシステム
|
|
EP4680728A1
(en)
|
2023-03-17 |
2026-01-21 |
Quell Therapeutics Limited |
Treg therapy
|
|
EP4434539A1
(en)
|
2023-03-20 |
2024-09-25 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
CN121586582A
(zh)
|
2023-03-20 |
2026-02-27 |
汉诺威医学院 |
嵌合抗原受体
|
|
WO2024193687A1
(en)
*
|
2023-03-23 |
2024-09-26 |
Nanjing Legend Biotech Co., Ltd. |
Inverted cytokine receptors and methods of use thereof
|
|
AU2024243972A1
(en)
*
|
2023-04-06 |
2025-10-23 |
Memorial Hospital For Cancer And Allied Diseases |
Il-10 receptor antibodies and methods of use thereof
|
|
CN116496417B
(zh)
*
|
2023-06-27 |
2023-10-10 |
北京市肿瘤防治研究所 |
含有膜型il7的融合蛋白及t细胞
|
|
CN121532418A
(zh)
*
|
2023-07-17 |
2026-02-13 |
南京传奇生物科技有限公司 |
融合蛋白及其使用方法
|
|
WO2026008994A1
(en)
|
2024-07-04 |
2026-01-08 |
Quell Therapeutics Limited |
Expression construct
|
|
GB202411558D0
(en)
|
2024-08-06 |
2024-09-18 |
Quell Therapeutics Ltd |
Culture method
|